

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

CD38-PE-Vio770

RRID:AB_2660383

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-099-158, RRID:AB_2660383

Antibody Information

URL: http://antibodyregistry.org/AB_2660383

Proper Citation: Miltenyi Biotec Cat# 130-099-158, RRID:AB_2660383

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 3-2019; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-990. (RRID:AB_2733229).

Antibody Name: CD38-PE-Vio770

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: IB6

Antibody ID: AB_2660383

Vendor: Miltenyi Biotec

Catalog Number: 130-099-158

Record Creation Time: 20250820T012029+0000

Record Last Update: 20250820T104017+0000

Ratings and Alerts

No rating or validation information has been found for CD38-PE-Vio770.

Warning: Discontinued: 2021

Discontinued: 3-2019; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-990. (RRID:AB_2733229).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.